| Literature DB >> 28991204 |
Yinyin Liao1,2, Lanting Zeng3,4, Pan Li5, Tian Sun6, Chao Wang7, Fangwen Li8, Yiyong Chen9,10, Bing Du11, Ziyin Yang12,13.
Abstract
Plant growth retardant (PGR) refers to organics that can inhibit the cell division of plant stem tip sub-apical meristem cells or primordial meristem cell. They are widely used in the cultivation of rhizomatous functional plants; such as Codonopsis Radix, that is a famous Chinese traditional herb. However, it is still unclear whether PGR affects the medicinal quality of C. Radix. In the present study, amino acid analyses, targeted and non-targeted analyses by ultra-performance liquid chromatography combined with time-of-flight mass spectrometry (UPLC-TOF-MS) and gas chromatography-MS were used to analyze and compare the composition of untreated C. Radix and C. Radix treated with PGR. The contents of two key bioactive compounds, lobetyolin and atractylenolide III, were not affected by PGR treatment. The amounts of polysaccharides and some internal volatiles were significantly decreased by PGR treatment; while the free amino acids content was generally increased. Fifteen metabolites whose abundance were affected by PGR treatment were identified by UPLC-TOF-MS. Five of the up-regulated compounds have been reported to show immune activity, which might contribute to the healing efficacy ("buqi") of C. Radix. The results of this study showed that treatment of C. Radix with PGR during cultivation has economic benefits and affected some main bioactive compounds in C. Radix.Entities:
Keywords: Codonopsis Radix; amino acid; plant growth retardant; polysaccharide; volatile
Mesh:
Substances:
Year: 2017 PMID: 28991204 PMCID: PMC6151746 DOI: 10.3390/molecules22101655
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Effect of plant growth retardant (PGR) on lobetyolin and atractylenolide III contents in C. Radix samples. (A) Chromatogram comparison of lobetyolin standard, and control and treatment groups. Lobetyolin (std.), lobetyolin standard (20 ng/μL, m/z = 397.1862, RT = 10.43 min); control, untreated C. Radix sample; treatment, PGR-treated C. Radix sample. (B) Chromatogram comparison of atractylenolide III standard, control and treatment groups. Atractylenolide III (std.), atractylenolide III standard (10 ng/μL, m/z = 249.1491, RT = 24.68 min). (C) & (D) Lobetyolin and atractylenolide III contents in control and treatment groups (as calculated from peak areas of samples and the standard).
Figure 2Effect of PGR on polysaccharides in C. Radix samples. Control, untreated C. Radix sample; treatment, PGR-treated C. Radix sample. The * indicates significant difference (p ≤ 0.05).
Effect of PGR on internal volatiles in C. Radix samples.
| Internal Volatile Metabolite | Treatment | Control | T/CK |
|---|---|---|---|
| Dodecane | 0.05 ± 0.01 | 0.09 ± 0.01 | 0.56 * |
| Hexadecane | 0.13 ± 0.01 | 0.23 ± 0.02 | 0.57 * |
| 2-Furanmethanol | 0.06 ± 0.01 | 0.13 ± 0.01 | 0.46 * |
| Phytane | 0.10 ± 0.01 | 0.17 ± 0.03 | 0.59 * |
| Octacosane | 0.05 ± 0.01 | 0.10 ± 0.01 | 0.50 * |
| Dihydroanethole | 0.27 ± 0.10 | 1.42 ± 0.28 | 0.19 * |
| Oxalic acid, dodecyl 2-methylphenyl ester | 0.05 ± 0.01 | 0.11 ± 0.01 | 0.46 * |
| Ethylhexyl benzoate | 0.04 ± 0.01 | 0.07 ± 0.00 | 0.57 * |
| Methyl hexadecanoate | 0.16 ± 0.01 | 0.24 ± 0.03 | 0.67 * |
| Diethyl Phthalate | 0.10 ± 0.01 | 0.14 ± 0.01 | 0.71 * |
| n-Heptadecylcyclohexane | 0.03 ± 0.00 | 0.06 ± 0.01 | 0.50 * |
| Methyl octadeca-9,12-dienoate | 0.11 ± 0.01 | 0.21 ± 0.04 | 0.52 * |
| Diisobutyl phthalate | 0.72 ± 0.08 | 1.10 ± 0.10 | 0.66 * |
| Phthalic acid, decyl 2,7-dimethyloct-7-en-5-yn-4-yl ester | 0.54 ± 0.07 | 0.79 ± 0.03 | 0.69 * |
The relative content of each compound from samples was calculated as GC-MS peak area ratio of analyte to n-ethyl decanoate (internal standard). Data are expressed as mean ± SD (n = 3). Control, untreated C. Radix sample; treatment, PGR-treated C. Radix sample. T/CK represents ratio of internal volatile content in PGR treatment to that in control. The * indicates significant difference (p ≤ 0.05).
Effect of PGR on free amino acids in C. Radix samples.
| Free Amino Acid | Treatment (μg/g) | Control (μg/g) | T/CK |
|---|---|---|---|
| Glutamic acid | 3234.18 ± 811.83 | 465.59 ± 174.63 | 6.95 * |
| Asparagine | 172.88 ± 44.88 | 34.36 ± 15.40 | 5.03 * |
| α-Aminoadipic Acid | 3270.40 ± 898.05 | 659.44 ± 244.17 | 4.96 * |
| Ornithine | 13.08 ± 1.59 | 6.41 ± 2.04 | 2.04 * |
| Taurine | 121.03 ± 85.58 | 7.56 ± 5.38 | 16.01 |
| Phosphatidylserine | 32.91 ± 16.27 | 10.05 ± 1.71 | 3.27 |
| Carbamide | 17619.48 ± 7948.53 | 9652.14 ± 3208.69 | 1.83 |
| Leucine | 22.65 ± 7.09 | 12.91 ± 4.08 | 1.75 |
| Arginine | 5431.27 ± 1205.33 | 3164.94 ± 1227.21 | 1.72 |
| Serine | 47.96 ± 11.59 | 32.21 ± 12.45 | 1.49 |
| Citrulline | 214.58 ± 74.13 | 149.97 ± 60.34 | 1.43 |
| β-Aminoisobutyric acid | 1.72 ± 0.42 | 1.28 ± 0.58 | 1.34 |
| Valine | 12.34 ± 2.41 | 9.42 ± 3.65 | 1.31 |
| Isoleucine | 61.95 ± 20.73 | 51.04 ± 16.87 | 1.21 |
| Lysine | 50.74 ± 9.78 | 44.94 ± 18.04 | 1.13 |
| β-Alanine | 4.93 ± 2.66 | 4.47 ± 2.49 | 1.10 |
| Phenylalanine | 18.95 ± 4.69 | 17.45 ± 5.79 | 1.09 |
| Alanine | 270.21 ± 102.56 | 291.28 ± 111.14 | 0.93 |
| Glycine | 0.00 ± 0.00 | 3.20 ± 1.10 | 0.00 * |
| Tyrosine | 8.98 ± 2.76 | 11.19 ± 4.72 | 0.80 |
| Histidine | 2448.93 ± 786.52 | 2454.37 ± 360.11 | 1.00 |
| γ-Aminobutyric acid | 27.76 ± 8.04 | 44.82 ± 10.31 | 0.62 |
| Tryptophan | 21.32 ± 8.14 | 37.35 ± 17.81 | 0.57 |
| Threonine | 9.96 ± 5.08 | 45.86 ± 53.54 | 0.22 |
Content of each amino acid was calculated based on the peak area of samples and the standard. Data are expressed as mean ± SD (n = 3). Control, untreated C. Radix sample; treatment, PGR-treated C. Radix sample. T/CK represents ratio of content in PGR treatment to that in control. The * indicates significant difference (p ≤ 0.05).
Figure 3Effect of PGR on secondary metabolites in C. Radix samples. CK, untreated C. Radix sample; T, PGR-treated C. Radix sample. (A–D) Principal component analysis (PCA) of secondary metabolites. (E–G) S-plot analysis of secondary metabolites, red marked points were selected for further identification. (A, E) Chromatographic separation performed using ACQUITY UPLC BEH Amide column in ESI negative mode. (B, F) Chromatographic separation performed using ACQUITY UPLC BEH Amide column in ESI positive mode. (C, G) Chromatographic separation performed using ACQUITY UPLC HSS T3 C18 column in ESI negative mode. (D) Chromatographic separation performed using ACQUITY UPLC HSS T3 C18 column in ESI positive mode.
Major secondary metabolites up-regulated by PGR.
| No. | Identification and Tentative Identification | Molecular Formula | RT (min) | T/CK | Mode | |
|---|---|---|---|---|---|---|
| 1 | Arginine | C6H14N4O2 | 0.70 | 173.1045[M − H]− | 1.57 * | C18, ES− |
| 2 | Verbascose | C30H52O26 | 0.75 | 827.2670[M − H]− | 1.71 ** | C18, ES− |
| 3 | (4-Aminomethyl-1,2,3-triazol-1-acetylamino)-5-hydroxybenzoic acid | C12H13N5O4 | 0.82 | 290.0883 [M − H]− | 2.23 ** | C18, ES− |
| 4 | 4-Mannopyranosyl-5- | C11H23O12P | 0.82 | 377.0859 [M − H]− | 1.62 * | C18, ES− |
| 5 | Acetylneuraminyl-galactose | C17H29NO14 | 0.82 | 470.1523 [M − H]− | 2.67 ** | C18, ES− |
| 6 | Deamino neuraminyl-galactosyl-acetyl glucosamine | C23H39NO19 | 0.82 | 632.2041 [M − H]− | 3.19 ** | C18, ES− |
| 7 | Glycoloyloxy-acetic acid | C4H6O5 | 0.87 | 133.0144 [M − H]− | 1.51 ** | C18, ES− |
| 8 | Bougainvillein-γ-I | C30H36N2O18 | 11.68 | 729.2257[M − NH4]− | 1.25 | Amide, ES− |
| 9 | Aurin | C19H14O3 | 20.27 | 307.1207[M+NH4]− | 1.72 ** | Amide, ES− |
| 10 | 9-Methylthio-2-nonanoic acid | C10H18O3S | 20.32 | 217.0906 [M − H]− | 1.38 ** | Amide, ES− |
| 11 | 5,6,7,8-Tetrahydromethanopterin | C30H45N6O16P | 7.20 | 794.3002[M+NH4] | 6.29 ** | Amide, ES+ |
CK, untreated C. Radix sample; T, PGR-treated C. Radix sample. T/CK, ratio of metabolite’s peak area in PGR-treated group to that in control group; The * and ** indicate significant differences (p ≤ 0.05 and p ≤ 0.01, respectively).
Major secondary metabolites down-regulated by PGR.
| No. | Identification and Tentative Identification | Molecular Formula | RT (min) | T/CK | Mode | |
|---|---|---|---|---|---|---|
| 1 | 3-Hexadecanoylamino-2-hydroxy-4-methylpentyl-phosphonic acid | C22H46NO5P | 1.05 | 453.3469[M + NH4] | 0.02 ** | Amide, ES+ |
| 2 | 4,4′-Dioxo-carotene-3,3′-diyl didecanoate | C60H88O6 | 1.05 | 905.6666[M + H]+ | 0.01 ** | Amide, ES+ |
| 3 | 1-Dimethylylidene-4-dihydrazinecarboximidamide-2,3-dimethoxybenzene | C12H18N8O2 | 4.18 | 324.1880[M + NH4] | 0.08 ** | Amide, ES+ |
| 4 | Phenylalanyl-glycyl-histidine | C17H21N5O4 | 1.74 | 358.1504 [M − H]− | 0.27 ** | C18, ES− |
CK, untreated C. Radix sample; T, PGR-treated C. Radix sample. T/CK, ratio of metabolite’s peak area in PGR-treated group to that in control group; The * and ** indicate significant differences (p ≤ 0.05 and p ≤ 0.01, respectively).
Figure 4Summary on effect of PGR on C. Radix samples.